Trial
NCT03739801
MM-398 and Ramucirumab in Treating Patients With Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
Phase IWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
University of Southern California
Collaborators
National Cancer Institute (NCI); Ipsen
Condition
Locally Advanced Unresectable Gastric Adenocarcinoma
Intervention
Liposomal Irinotecan
Why stopped
PI left
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-03-27